Lee Oh-Hyun, Roh Ji Woong, Kim Yongcheol, Son Nak-Hoon, Cho Jay Yi, Jang Daesek, Im Eui, Cho Deok-Kyu, Choi Donghoon
Division of Cardiology, Department of Internal Medicine, Yonsei University College of Medicine and Cardiovascular Center, Yongin Severance Hospital, Yongin, South Korea.
Department of Statistics, Keimyung University, Daegu, South Korea.
Front Cardiovasc Med. 2023 Mar 1;10:1007147. doi: 10.3389/fcvm.2023.1007147. eCollection 2023.
The distal radial approach (DRA) for coronary catheterization is increasingly being used worldwide yet the optimal medication regimen to prevent radial artery spasm (RAS), an important factor for the success of the procedure, remains unclear. The aim of this study is to examine the effectiveness of medication for preventing RAS via the DRA.
This was a prospective, comparative randomized study including 400 patients who underwent coronary catheterization via DRA in single center by three experienced DRA operators. Patients were randomized to either nitroglycerin (NTG) injection ( = 200) or NTG plus verapamil ( = 200) to compare the effectiveness and safety of these regimens.
There were no differences between the groups in the changes in radial artery diameter at most spastic area (0.34 ± 0.20 in the NTG group, 0.35 ± 0.20 in the NTG plus verapamil group; = 0.73). There was no difference between the groups in the ratio of patients without arm pain during the procedure (95.0% in the NTG group, 93.5% in the NTG plus verapamil group; = 0.67). However, there was a greater reduction in diastolic blood pressure in the NTG plus verapamil group (-8.3 ± 7.9 mmHg) than in the NTG group (-6.6 ± 7.6 mmHg) ( = 0.03).
Intra-arterial injection of NTG as a single agent is effective and safe in the prevention of RAS during coronary catheterization via the DRA compared with a cocktail regimen of NTG plus verapamil.
https://cris.nih.go.kr, identifier KCT0005177.
桡动脉远端入路(DRA)用于冠状动脉导管插入术在全球范围内越来越多地被使用,但预防桡动脉痉挛(RAS)的最佳药物方案仍不明确,而RAS是该手术成功的一个重要因素。本研究的目的是探讨通过DRA预防RAS的药物疗效。
这是一项前瞻性、比较性随机研究,纳入了在单中心由三名经验丰富的DRA手术医生通过DRA进行冠状动脉导管插入术的400例患者。患者被随机分为硝酸甘油(NTG)注射组(n = 200)或NTG加维拉帕米组(n = 200),以比较这些方案的有效性和安全性。
两组在最痉挛部位的桡动脉直径变化方面无差异(NTG组为0.34±0.20,NTG加维拉帕米组为0.35±0.20;P = 0.73)。两组在手术过程中无手臂疼痛的患者比例方面无差异(NTG组为95.0%,NTG加维拉帕米组为93.5%;P = 0.67)。然而,NTG加维拉帕米组的舒张压下降幅度(-8.3±7.9 mmHg)大于NTG组(-6.6±7.6 mmHg)(P = 0.03)。
与NTG加维拉帕米的联合用药方案相比,动脉内注射单一药物NTG在通过DRA进行冠状动脉导管插入术期间预防RAS方面是有效且安全的。